Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means

Bullish+30.21%
19 Aug, 16:54
Source: Decrypt

AI Summary

Moderna shares surged 131% on Phase 3 cancer vaccine trial success against standard of care, causing $4.8 billion in short seller losses.

A Phase 3 win against the standard of care sent the biotech's shares up 131% and left short sellers down $4.8 billion.